Morocco Slashes Prices on 70 Medicines, Including Cancer Treatments

This revision comes in accordance with Ministerial Order No. 19.3976 on the revision of the public sale prices of branded, generic and biosimilar medicines marketed in Morocco.

The price review recorded in the latest issue of the Official Bulletin mainly concerns medicines used in the treatment of certain cancers. Branded and generic products are also included.

Among these medicines, Alimta, used in the monotherapy treatment of certain cancers, is offered at 6,197 DH instead of 8,725 DH.

Among the branded products whose prices are set, there are Mabthera (18,146 DH) indicated in the treatment of several lymphomas as well as chronic lymphocytic leukemia. Smidax for the short-term treatment of heart failure (5 ml at 7,987 MDH) or Zinforo (4,589 DH), recommended in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.